ABL Bio Inc.
KOSDAQ-listed antibody biotech developing pipelines via its Grabody™ bispecific antibody platform for global out-licensing.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2016 and listed on KOSDAQ in 2018, ABL Bio is an antibody therapeutics R&D company. It develops pipeline candidates based on its proprietary bispecific antibody platform Grabody™ and pursues a business model centered on out-licensing them to global pharmaceutical companies. It applies a strict Decision Review System to decide whether to continue programs, discontinuing early those with limited value upside, shares out-licensing benefits with partners who contributed to development to incentivize co-development, and also pursues in-licensing to expand its pipeline.
Clinical trials
data.go.kr5 MFDS clinical trial authorisations · 2017–2025 (Phase 1 3 · Phase 1/2 1 · Phase 1/2a 1)
- Phase 1/2ABL1032025-06-02
12 trial sites
- Phase 1ABL1032023-08-09
14 trial sites
- Phase 1ABL5032023-03-29
5 trial sites
- Phase 1ABL5012021-08-03
6 trial sites
- Phase 1/2aHDB001A2017-08-29
7 trial sites
R&D and key agreements
Source: DART corporate disclosureGrabody™ 이중항체 플랫폼 · 플랫폼 기술 · Proprietary bispecific antibody platform used to develop pipeline candidates for out-licensing
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition